C92.5 Acute myelomonocytic leukemia

Name of the Condition

• Acute Myelomonocytic Leukemia

Summary

Acute myelomonocytic leukemia (AMML) is a subtype of acute myeloid leukemia (AML) characterized by the rapid proliferation of abnormal myeloblasts and monoblasts in the bone marrow. This uncontrolled growth disrupts normal blood cell production, leading to deficiencies in red blood cells, platelets, and functional white blood cells. AMML is classified as an acute leukemia due to its rapid onset and progression.

Causes

AMML arises from genetic mutations in hematopoietic stem cells, which disrupt normal cell differentiation and promote uncontrolled proliferation. These mutations may occur spontaneously or be acquired. Common mutations involve genes such as FLT3, NPM1, and RUNX1, which affect cell growth and survival pathways.

Risk Factors

• Age: Primarily affects older adults, with incidence increasing after age 60.
• Previous chemotherapy or radiation therapy for other cancers.
• Exposure to high levels of benzene or other industrial chemicals.
• Genetic disorders, including Down syndrome and Fanconi anemia.
• Myelodysplastic syndromes or other pre-existing bone marrow diseases.

Symptoms

• Fatigue, weakness, or shortness of breath due to anemia.
• Easy bruising, bleeding, or petechiae from low platelet counts.
• Frequent or severe infections due to neutropenia.
• Unexplained fever or weight loss.
• Bone or joint pain.

Diagnosis

Diagnosis involves blood tests to assess cell counts and abnormalities, followed by a bone marrow biopsy to examine cell morphology and genetic markers. Additional tests, such as cytogenetic or molecular analysis, may identify specific mutations.

Treatment Options

Treatment depends on the subtype and patient-specific factors, including age and overall health. Common approaches include chemotherapy, targeted therapy, and stem cell transplantation. Supportive care, such as blood transfusions or antibiotics, may also be necessary.

Prognosis and Follow-Up

Prognosis varies based on factors like age, genetic mutations, and response to treatment. Regular follow-up is essential to monitor for recurrence or complications. Long-term survival rates depend on individual risk profiles and treatment effectiveness.

Complications

• Infections due to neutropenia.
• Bleeding or bruising from thrombocytopenia.
• Anemia-related fatigue or shortness of breath.
• Organ infiltration by leukemic cells.
• Treatment-related side effects, such as nausea or organ toxicity.

Lifestyle & Prevention

• Avoid exposure to known carcinogens, such as benzene.
• Maintain a healthy lifestyle to support overall immune function.
• Follow recommended screening for high-risk individuals.
• Discuss genetic counseling if a hereditary predisposition is suspected.

When to Seek Professional Help

Seek immediate medical attention for persistent symptoms like unexplained fever, severe fatigue, or unusual bleeding. Prompt evaluation is critical for early diagnosis and treatment.

Tips for Medical Coders

When coding for acute myelomonocytic leukemia (C92.5), ensure documentation supports the diagnosis, including clinical findings, laboratory results, and treatment plans. Verify that the code aligns with the specific subtype and any associated complications. Accurate coding requires clear differentiation from other AML subtypes and adherence to ICD-10-CM guidelines.